Evommune, Inc. (EVMN)
13.67
-0.35
(-2.50%)
USD |
NYSE |
Aug 24, 16:00
13.66
-0.01
(-0.07%)
After-Hours: 20:00
Evommune Total Liabilities (Quarterly) : 24.36M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.36M |
| March 31, 2026 | 17.90M |
| December 31, 2025 | 19.38M |
| Date | Value |
|---|---|
| September 30, 2025 | 267.68M |
| June 30, 2025 | 267.44M |
| March 31, 2025 | 214.25M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 20.05M |
| Mineralys Therapeutics, Inc. | 116.94M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 301.95M |
| Shareholders Equity (Quarterly) | 277.59M |
| Debt to Equity Ratio | 0.0311 |
| Current Ratio | 11.68 |
| Net Debt Paydown Yield | 7.65% |